Frontlight ResearchEarly access
Taking people in GermanyPhase 2
Inhaled ColiFin for a new Pseudomonas aeruginosa infection in adults with bronchiectasis
Tests inhaled ColiFin against usual care in adults with bronchiectasis and new Pseudomonas aeruginosa.
Key facts
- Who runs it
- Philipps-Universitaet Marburg
- Where
- Berlin, Cologne, Duesseldorf, Essen, Frankfurt Am Main, Hanover, Loewenstein, Luebeck, Marburg, Munich, Stuttgart, and Wangen Im Allgaeu, GermanySee the 13 sites
- Trial code
- EU 2023-509277-22-00
- EudraCT 2021-002335-33
- DRKS00028518
- Registry title
- Inhalation therapy in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 66 people, planned
- Started
- 22 Jun 2022
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bronchiectasis (widened, damaged airways) who recently had Pseudomonas aeruginosa (PA) found in their sputum without new symptoms. It compares inhaled ColiFin® with standard care.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Bronchiectasis confirmed by chest CT scan. No new or worse breathing symptoms in the 2 months before the new PA result.
- Earlier treatment
- Cannot join after inhaled antibiotics or long-term (≥3 months) pseudomonas-active treatment in the past 5 years. No pseudomonas-active antibiotics between the new PA result and the start visit.
- Biomarker or test result
- A new positive sputum culture for PA, not older than 12 weeks at screening.
Main reasons for not taking part
- Bronchiectasis caused by cystic fibrosis
- Pregnant or breastfeeding women
- Strongly reduced kidney function, GFR ≤ 30 ml/min
- Known PA infection in the 5 years before the new result
- Allergy or intolerance to ColiFin®, colistin or other polymyxins; myasthenia gravis, porphyria, or ppFEV1 < 30%
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Age ≥ 18 years at screening
- Bronchiectasis verified by chest CT scan
- New positive sputum culture for PA (not older than 12 weeks at screening)
- No recent onset of new respiratory symptoms or worsening of pre-existing respiratory symptoms (e.g. cough, sputum amount, sputum colour, sputum viscosity, haemoptysis, decreased exercise capacity, malaise, fatigue etc.) over the last 2 months before new positive PA sputum culture, as per investigator judgement
- Written informed consent
- Negative serum/urine pregnancy test in women of childbearing potential (WOCBP) at screening
- WOCBP must agree to maintain a highly effective method of contraception during study treatment and at least 4 weeks thereafter
- Male subjects have to use condom during treatment and until the end of relevant systemic exposure in the male subject, plus a further 90-day period and non-pregnant WOCBP partner have to use any contraception method additionally
Who cannot take part
- Known prior infection with PA in the past 5 years before the new positive PA culture
- Treatment with pseudomonas-active antibiotics in the period between new PA positive sputum culture and baseline visit
- Any treatment with inhaled antibiotics or long-term pseudomonas-active treatment (≥3 months) in the past 5 years before screening
- Known intolerance to ColiFin® in prior medical history
- strongly impaired renal function, GFR ≤ 30 ml/min
- Hypersensitivity/Known intolerance to Colistimethate sodium, Colistin, polymyxin B or to other polymyxins
- Bronchiectasis due to cystic fibrosis
- Pregnant women
- Breast feeding women
- Participation in any other interventional clinical trial
- Planned pseudomonas-active antibiotic treatment during the time of study participation
- Known diagnosis of myasthenia gravis or porphyria
- ppFEV1 < 30% (post-bronchodilator)
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Helios Klinikum Emil von Behring GmbHBerlin, GermanyTaking people
- Augustinerinnen Krankenhaeuser gGmbHCologne, GermanyTaking people
- Universitaetsklinikum Duesseldorf AöRDuesseldorf, GermanyTaking people
- Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbHEssen, GermanyTaking people
- Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
- SLK-Kliniken Heilbronn GmbHLoewenstein, GermanyTaking people
- Universitaetsklinikum Schleswig-Holstein AöRLuebeck, GermanyTaking people
- Philipps-Universitaet MarburgMarburg, GermanyTaking people
- Ludwig Maximilian University Of MunichMunich, GermanyTaking people
- Robert Bosch Krankenhaus GmbHStuttgart, GermanyTaking people
- Waldburg-Zeil Akutkliniken GmbH & Co. KGWangen Im Allgaeu, GermanyTaking people
About the trial
What the trial wants to find out
To evaluate the effect of ColiFin® therapy compared to SOC sputum/airway culture negativity for PA 28 weeks after randomization.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Inhaled ColiFin® in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection – an open-label, proof of concept - randomized controlled trial (DZL-Eradicate)
- Plain-language title
- Inhaled ColiFin for a new Pseudomonas aeruginosa infection in adults with bronchiectasisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 16 October 2026